# Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

> **NCT07370337** · PHASE2 · RECRUITING · sponsor: **Eye & ENT Hospital of Fudan University** · enrollment: 50 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of External Auditory Canal
- Locally Advanced Tumor

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT07370337
- **Lead sponsor:** Eye & ENT Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07370337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07370337, "Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT07370337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*